Dex as Analgesic Adjuvant in OSA Patients
Klíčová slova
Abstraktní
Popis
BACKGROUND/STUDY SIGNIFICANCE
Patients with OSA undergoing surgery have increased surgical risk compared to patients that do not have OSA . Perioperative medication such as benzodiazepines and opioids can decrease upper airway tone, inhibit central respiratory drive and inhibit upper airway reflexes. The supine position may also worsen the severity of the OSA. Additionally, this group of patients is more likely to have a higher incidence of complications, particularly post operative hypoxemia , difficult intubation , and complicated extubation course .
Uvulopalatopharyngoplasty (UPPP) along with other tongue base procedures are commonly performed surgical procedures used to help alleviate the symptoms of obstructive sleep apnea (OSA). Postoperative management of oropharyngeal pain is challenging since narcotic administration may compromise respiratory status in OSA patients. The Anesthesiology and Otorhinolaryngology communities have begun to rethink acceptable narcotic use in OSA patients especially following the recent FDA announcement highlighting serious adverse effects related to codeine consumption in children who had undergone tonsillectomies.
Dexmedetomidine (Precedex) is a sedative with minimal respiratory depression. Its mechanism is via alpha 2 agonism and has 8 times the affinity for the alpha 2 adrenoreceptor than clonidine. It has been shown to have sedative, analgesic, and anxiolytic effects. It produces a predictable and dose dependent decrease in heart rate and blood pressure. Dexmedetomidine undergoes extensive metabolism in the liver and is then eliminated as methyl and glucuronide conjugates mostly via the renal system. The pharmacokinetics are markedly affected by hepatic insufficiency .
Termíny
| Poslední ověření: | 07/31/2018 |
| První předloženo: | 03/19/2018 |
| Odhadovaná registrace vložena: | 07/31/2018 |
| První zveřejnění: | 08/02/2018 |
| Poslední aktualizace byla odeslána: | 07/31/2018 |
| Poslední aktualizace zveřejněna: | 08/02/2018 |
| Aktuální datum zahájení studie: | 06/30/2014 |
| Odhadované datum dokončení primární: | 05/31/2015 |
| Odhadované datum dokončení studie: | 05/31/2015 |
Stav nebo nemoc
Intervence / léčba
Drug: Dexmedetomidine Sedation
Drug: Placebo
Fáze
Skupiny zbraní
| Paže | Intervence / léčba |
|---|---|
| Experimental: Dexmedetomidine Sedation This group will receive 1mcg/kg bolus of dexmedetomidine over 15 minutes after intubation followed by an infusion of dexmedetomidine at 0.5mcg/kg/hr until approximately 30 minutes before the end of surgery. | Drug: Dexmedetomidine Sedation Dexmedetomidine is an alpha-2 agonist that provides both sedation and analgesia |
| Placebo Comparator: Placebo This group will receive a colorless, odorless liquid (i.e. normal saline) in order to resemble Dexmedetomidine. | Drug: Placebo saline solution |
Kritéria způsobilosti
| Věky způsobilé ke studiu | 18 Years Na 18 Years |
| Pohlaví způsobilá ke studiu | All |
| Přijímá zdravé dobrovolníky | Ano |
| Kritéria | Inclusion Criteria: - Age 18 or older - Patients scheduled for UPPP - Patients with diagnosis of OSA via polysomnography - American Society of Anesthesiology (ASA) classification 3 or lower Exclusion Criteria: - Bradycardia as defined as resting heart rate <60 Beats per min (BPM) or symptomatic - Any degree of heart block diagnosed by ECG - Hypotension as defined as <20% from baseline or symptomatic - Liver failure, (two fold rise in liver enzymes) - Chronic Kidney Disease (CKD) III or greater - History of allergy to opioids or dexmedetomidine - ASA classification 4 or higher - ICU or Step down admission - Difficult airway as defined by previous history of difficult intubation or requiring a fiberoptic intubation. |
Výsledek
Primární výsledná opatření
1. Pain Score [within 24 hours post-operative]
Měření sekundárních výsledků
1. Pain Score [within 24 hours post-operative]
2. Nausea [within 24 hours post-operative]
3. Hypoxia [within 24 hours post-operative]
4. Length of hospital stay [from admission to discharge, up to 14 days]
5. Sedation [within 24 hours post-operative]
6. Time to extubation [from post-operative until extubation, up to 72 hours]
7. Number of participants experiencing vomiting [within 24 hours post-operative]
